1. Home
  2. CFFI vs SGMT Comparison

CFFI vs SGMT Comparison

Compare CFFI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CFFI
  • SGMT
  • Stock Information
  • Founded
  • CFFI 1927
  • SGMT 2006
  • Country
  • CFFI United States
  • SGMT United States
  • Employees
  • CFFI N/A
  • SGMT N/A
  • Industry
  • CFFI Major Banks
  • SGMT
  • Sector
  • CFFI Finance
  • SGMT
  • Exchange
  • CFFI Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • CFFI 218.0M
  • SGMT 238.7M
  • IPO Year
  • CFFI 1998
  • SGMT 2023
  • Fundamental
  • Price
  • CFFI $68.86
  • SGMT $7.39
  • Analyst Decision
  • CFFI
  • SGMT Strong Buy
  • Analyst Count
  • CFFI 0
  • SGMT 8
  • Target Price
  • CFFI N/A
  • SGMT $29.75
  • AVG Volume (30 Days)
  • CFFI 3.7K
  • SGMT 570.9K
  • Earning Date
  • CFFI 10-23-2025
  • SGMT 11-13-2025
  • Dividend Yield
  • CFFI 2.65%
  • SGMT N/A
  • EPS Growth
  • CFFI 43.03
  • SGMT N/A
  • EPS
  • CFFI 8.09
  • SGMT N/A
  • Revenue
  • CFFI $125,432,000.00
  • SGMT N/A
  • Revenue This Year
  • CFFI N/A
  • SGMT N/A
  • Revenue Next Year
  • CFFI N/A
  • SGMT N/A
  • P/E Ratio
  • CFFI $8.43
  • SGMT N/A
  • Revenue Growth
  • CFFI 9.28
  • SGMT N/A
  • 52 Week Low
  • CFFI $53.14
  • SGMT $1.73
  • 52 Week High
  • CFFI $89.90
  • SGMT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • CFFI 50.06
  • SGMT 44.02
  • Support Level
  • CFFI $66.48
  • SGMT $7.21
  • Resistance Level
  • CFFI $71.25
  • SGMT $8.84
  • Average True Range (ATR)
  • CFFI 1.19
  • SGMT 0.62
  • MACD
  • CFFI -0.18
  • SGMT -0.09
  • Stochastic Oscillator
  • CFFI 49.79
  • SGMT 19.69

About CFFI C&F Financial Corporation

C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: